Aims/hypothesis There has been long-standing debate about whether diabetes is a causal risk factor for pancreatic cancer or a consequence of tumour development. Prospective epidemiological studies have shown variable relationships between pancreatic cancer risk and blood markers of glucose and insulin metabolism, overall and as a function of lag times between marker measurements (blood donation) and date of tumour diagnosis. 
Introduction
Well-established lifestyle and environmental risk factors for exocrine pancreatic cancer include smoking [1, 2] , chronic and acute forms of pancreatitis [3] , and excess body weight [4] , although the last is a rather weak risk factor for pancreatic cancer in comparison with several other cancer types [5] .
A further, well-documented risk factor for pancreatic cancer is long-standing diabetes, although many studies have also documented the occurrence of diabetes relatively shortly before diagnosis of a pancreatic tumour. This adds fuel to the debate on whether diabetes is a possible cause or, more likely, a consequence of tumour development [6, 7] . In relation to the first theory, it has been speculated that elevated plasma glucose levels and/or increased pancreatic insulin secretion, which are both intrinsic to the development of type 2 diabetes, could serve as possible mechanisms explaining the risk association between diabetes and pancreatic tumour development (e.g. by stimulating cellular growth and by inhibiting apoptosis [8, 9] ). According to the second theory, diabetes would occur primarily as a result of a developing tumour, which progressively may entrap or invade pancreatic beta cell islets [10] , thus causing a gradual destruction of functional beta cell capacity [11] , reductions in insulin secretion capacity, and progressive hyperglycaemia.
To further elucidate the possible cause-and/or-effect relationships between diabetes mellitus and pancreatic cancer, it is important to further elucidate the temporal relationship between pancreatic cancer occurrence and preexisting disturbances of glucose and insulin metabolism. Previous prospective studies have shown statistically significant associations of pre-diagnostic glucose [12] [13] [14] [15] and insulin levels [15, 16] with pancreatic cancer risk; however, results were inconsistent when lag time was taken into consideration.
Here, we report results from a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC), measuring pre-diagnostic serum levels of HbA 1c and C-peptide in healthy individuals at enrolment, to calculate risk estimates for the association of those markers with pancreatic cancer. To examine the complex, possibly time-dependent relationship of glucose, insulin, diabetes and pancreatic cancer, we additionally stratified our analyses by lag time between study enrolment (with blood donation) and pancreatic cancer diagnosis.
Methods

Study population
The design and methods of the EPIC study have been described by Haftenberger et al. and Riboli et al. [17, 18] . Briefly, 519,978 men and women, mostly aged between 35 and 70 years, were recruited by 23 collaborating centres in ten European countries (Denmark, France, Germany, Greece, Italy, the Netherlands, Norway, Spain, Sweden and the UK) between 1992 and 2000. Ethical review boards of the International Agency for Research on Cancer (IARC) and local institutions gave approval for the study and all participants provided informed consent.
Blood sample collection and storage In seven EPIC countries (France, Germany, Greece, Italy, the Netherlands, Spain and the UK) serum, plasma, erythrocytes and DNA were aliquoted and stored in liquid nitrogen (−196°C) in a central biorepository. In Denmark, blood samples were stored locally in nitrogen vapour (−150°C) and in Sweden in freezers at −70°C. For the present study, Norway was excluded because blood samples had only recently been collected and very few pancreatic cancer cases had been diagnosed after blood donation.
Follow-up for cancer incidence and vital status Incident cancer cases were identified by population cancer registries (Denmark, Italy, the Netherlands, Spain, Sweden and the UK) or by a combination of methods including health insurance records, cancer and pathology registries and active follow-up of study participants (France, Germany, Greece). In all EPIC centres, data on vital status are collected through mortality registries, in combination with health insurance data (France) or active follow-up (Greece). For the present project on pancreatic cancer, the study period was defined as the latest date of complete follow-up for both cancer incidence and vital status in each EPIC centre, and varied from December 2002 to December 2006. For Germany, Greece, and France, the end of follow-up was considered to be the last known contact, the date of diagnosis or the date of death, whichever came first.
Selection of case and control participants Pancreatic cancer incidence data were coded according to ICD-10 (www.who.int/classifications/icd/en/) and included all invasive exocrine pancreatic cancers that were coded as C25 (25.0-25.3, 25.7-25.9) . Exclusion criteria were the occurrence of other malignant tumours preceding the diagnosis of pancreatic cancer, except for non-melanoma skin cancer, and the non-availability of blood specimens. By the end of December 2006, 638 incident cases of pancreatic cancer were identified, of which 578 were primary exocrine pancreatic tumours. For 466 of these cases blood specimens were available. Of these, 342 (76%) were microscopically confirmed. For the remaining 24% diagnosis was confirmed by clinical symptoms, imaging results and/or physical examination. For each case, one control participant, alive and free of cancer at time of diagnosis of the index case, was selected using incidence density sampling. Matching characteristics were study centre, sex, age at enrolment (±6 months), date at entry in the cohort, time between blood sampling and time of last consumption of food and drink (<3, 3-6, ≥6 h). [19] , the highest HbA 1c category was further divided into these two groups. ORs were also computed to assess the association of diabetes with pancreatic cancer risk. In general, participants were defined as having diabetes if they self-reported the condition at recruitment and/or had HbA 1c levels ≥6.5% (48 mmol/mol) at baseline (n=95).
Laboratory assays
Conditional logistic regression was also used to assess the association of possible confounders with pancreatic cancer risk other than those controlled for by matching; these include BMI (continuous), waist circumference (continuous), WHR (continuous), alcohol intake at recruitment (continuous), physical activity (active, moderately active, moderately inactive, inactive), smoking status (never, former, current, missing), and diabetes at recruitment (yes, no, missing). Variables remained in the model if they were associated with pancreatic cancer, correlated with HbA 1c or C-peptide, or changed the logistic β estimate by more than 10%. We finally adjusted for BMI as a continuous variable and for smoking status as a categorical variable (never smoker; former smoker who stopped less than 10 years ago; former smokers who stopped 10 or more years ago; current smokers with 1-9, 10-19, or ≥20 cigarettes per day; smoking status unknown). To explore other possible confounding effects, we additionally adjusted for C-peptide or HbA 1c in further models.
In addition, analyses were stratified by factors that could modify the relationship between HbA 1c or C-peptide levels and pancreatic cancer. Tests for statistical heterogeneity between subgroups were calculated by adding crossproduct terms in the logistic regression models over quartiles of HbA 1c and C-peptide and testing the significance with the Wald test, adjusted for confounders.
All statistical analyses were conducted using the Statistical Analysis System (SAS) software package, Version 9.2 (SAS Institute, Cary, NC, USA).
Results
Baseline characteristics of the study population are shown in Table 1 . Mean follow-up time for cases was 5.3 years (range 0-13 years). Of those with pancreatic cancer, 32% were current smokers compared with 22% of controls, whereas never smokers were more common among controls than among cases. At baseline recruitment, diabetes, either self-reported or defined by elevated HbA 1c level, was more frequent among those who developed pancreatic cancer.
Among women, those with incident pancreatic cancer had significantly higher BMI and waist circumference than their matched controls but no significant differences in BMI or waist circumference were seen among men (Table 1) . Stratifying by smoking and diabetes status, significant case-control differences in BMI and waist circumference appeared to be restricted to never-smoking diabetes patients. Case-control differences in HbA 1c were greatest among former smokers, and particularly among former smokers who were also diabetic at baseline (mean cases (Table 2) . Multivariate adjustment for BMI or waist circumference, and smoking status as well as C-peptide levels only slightly attenuated this risk association.
Analyses by lag time between the date of blood donation (biomarker measurements) and date of pancreatic cancer diagnosis showed no statistically significant heterogeneity of the association of HbA 1c with pancreatic cancer risk, although the association was somewhat stronger for participants with follow-up times longer than the median length of follow-up of 5.2 years than for those with shorter follow-up times ( Although trend tests over categories of HbA 1c did not show a statistically significant heterogeneity by smoking status, stratification by smoking status did reveal a clearly stronger increase in pancreatic cancer risk with increasing HbA 1c concentration for never smokers, a somewhat weaker increase in risk among ex-smokers, and no increase in risk with increasing HbA 1c among current smokers ( Table 2) .
Associations of C-peptide with cancer risk Overall, Cpeptide concentrations showed no significant relationship with pancreatic cancer risk (Table 3) . Multivariate adjustments for BMI or waist circumference, smoking categories, or HbA 1c , or exclusion of diabetic individuals did not materially change these OR estimates. However, among those who had provided a blood sample under fasting conditions (last food consumption ≥6 h ago), increasing Cpeptide levels did show a tendency to increase risk of pancreatic cancer, although the risk was not statistically significant (Table 3) .
OR estimates for increasing C-peptide levels did not vary by length of follow-up or smoking status (data not shown).
Further analyses stratified by sex, diabetes status, median BMI or waist circumference did not show statistically significant heterogeneity between these strata for risk associations with HbA 1c or C-peptide (data not shown).
Discussion
In this prospective study, we observed an increase in pancreatic cancer risk with increasing pre-diagnostic HbA 1c levels, even for participants with HbA 1c levels within the non-diabetic range. The association was only slightly weakened and remained statistically significant after adjustment for BMI or smoking status, and in stratified analyses was most apparent among never smokers. Contrary to HbA 1c , pre-diagnostic levels of C-peptide showed no significant associations with pancreatic cancer risk, irrespective of smoking or fasting status. Lag-time analyses showed no clear difference in the association of pancreatic cancer c Logistic regression conditioned on matching factors (EPIC recruitment centre, sex, age at recruitment, date at entry in the cohort, time between blood sampling and last consumption of foods and drinks). Adjusting variables in further model: smoking (never smoker; former smoker who stopped <10 years ago, ≥10 years ago; current smokers with 1-9, 10-19, or ≥20 cigarettes per day; smoking status unknown) and BMI (continuous) d Self-reported diabetes at recruitment and/or HbA 1c ≥6.5% (48 mmol/mol) e Unconditional logistic regression, adjusted for matching factors (EPIC recruitment centre, sex, age at recruitment, date at entry in the cohort, time between blood sampling and last consumption of foods and drinks). Adjusting variables in subgroup analysis by median BMI: smoking (never smoker; former smoker who stopped <10 years ago, ≥10 years ago; current smokers with 1-9, 10-19 or ≥20 cigarettes per day; smoking status unknown [19] . With few exceptions [20] , previous prospective studies have shown statistically significant associations of pre-diagnostic glucose levels with pancreatic cancer risk [12] [13] [14] [15] . In these studies, a clear increase in risk was also visible among individuals with intermediate, non-diabetic levels of glycaemia.
Our findings for C-peptide-no significant association with pancreatic cancer risk overall, under fasting or nonfasting conditions-contrast with those from other studies. In a study of four pooled prospective cohorts in the USA, Michaud et al. did observe an increase in pancreatic cancer risk for the highest quartile level of non-fasting plasma Cpeptide, but no association with fasting C-peptide [16] . In the Finnish ATBC cohort, by contrast, pancreatic cancer risk was significantly elevated for the highest quartile of fasting serum insulin [15] .
Obesity is an important and frequent determinant of insulin resistance and chronic hyperinsulinaemia [21] , and a very strong risk factor for type 2 diabetes [22] . Paradoxically, globally, epidemiological studies have shown only very modest associations of pancreatic cancer risk with BMI or other anthropometric measures of adiposity [4] . Our data showed clear positive correlations of BMI or waist circumference with C-peptide, but very little correlation of these adiposity indices with HbA 1c (data not shown), in line with findings from other studies [23, 24] . Adiposity-related insulin resistance, while leading to increased plasma insulin levels, may generally not be the only, or even principal, cause of increases in blood glucose levels. Indeed, hyperglycaemia is generally related to a degree of pancreatic beta cell deficiency and insufficient insulin secretion in response to rising glucose levels, and such deficiency is also a central hallmark of all major forms of diabetes. The molecular-pathological pathways leading to the deficiency vary between different forms of diabetes, and it is conceivable that relatively specific forms of pancreatic pathology are at the origin of the hyperglycaemia in individuals who subsequently develop pancreatic cancer. Based on observations indicating that inflammatory pathways play a very central role in the development of pancreatic cancer [25, 26] while potentially contributing also to the development of diabetes [27] , we speculate that such specific pathology could be a form of chronic and low-grade pancreatic inflammation.
Under the hypothesis that, indeed, a chronic and low-grade form of pancreatic pathology is an original cause of hyperglycaemia in individuals who later develop pancreatic malignancies, we examined whether there are signs of moderate and progressive impairment of the pancreatic beta cell responsiveness, as time intervals till diagnosis of a pancreatic tumour get shorter. Our analyses, however, showed only little heterogeneity of the associations of C-peptide and HbA 1c levels with pancreatic cancer risk by length of lag time to cancer diagnosis. Similar lag-time analyses in other prospective studies have led to inconsistent findings so far. In the pooled US cohort [16] and the ATBC cohort [15] , there were indications of a stronger association of C-peptide and fasting insulin and glucose levels, respectively, with longer follow-up, whereas two other prospective cohort studies on blood glucose levels and pancreatic cancer risk showed no heterogeneity of these associations by lag time [12, 13] .
A major strength of our nested case-control study is its prospective design, reducing to a certain extent the possibility of reverse causation, whereas a limitation is the single assessment of biochemical indicators, which may be susceptible to biological variation.
In conclusion, the results of our nested case-control study embedded in a large multi-centre cohort support an association of increasing HbA 1c levels with pancreatic cancer risk, independent of BMI or diabetes status. However, in contrast to some previous studies, we did not find an association of elevated C-peptide with pancreatic cancer risk. Overall, combining the results from prospective studies so far, data provide no coherent picture in terms of progressive alterations in glucose and/or insulin metabolism at greater or shorter time intervals prior to pancreatic cancer diagnosis. Further research is needed to understand whether elevated plasma glucose is a possible contributing cause for pancreatic cancer, or whether it is a mere epi-phenomenon pointing towards the existence of a moderate pancreatic disorder that predisposes to the development of pancreatic cancer as well as to diabetes.
